Results

Total Results: 1,187 records

Showing results for "weeks".

141. Noninvasive Treatments for Low Back Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/back-pain-treatment_research_executive.pdf
     February 01, 2016 - costs.5 The prognosis for acute low back pain (generally defined as an episode lasting less than 4 weeks … persistent symptoms, continued improvement is often seen in the subacute phase between 4 and 12 weeks … This report focuses on adults with low back pain of any duration (categorized as acute [<4 weeks], … subacute [4–12 weeks], and chronic [≥12 weeks]), including nonradicular low back pain, radicular low … ; effects were less pronounced at 52 weeks.

142. Major-Depressive-Disorder Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/major-depressive-disorder_executive.pdf
     December 01, 2015 - Study durations ranged from 4 to 96 weeks. … After 24 weeks of followup, however, SGAs led to higher rates of overall discontinuation than CBT ( … SGAs and PSYD also led to similar rates of overall discontinuation over 8 to 16 weeks (low SOE), 48 … weeks (low SOE), and 96 weeks of followup (low SOE). … 96 weeks of followup compared with SGA monotherapy (low SOE).

143. Ace-Inhibitor-Arb-Update-Surveillance-160328 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update-surveillance-160328.pdf
     May 29, 2025 - RCTs,$non"RCTs,$cohorts,$etc.)h$cross" sectional$studies$OK$if$time$on$treatment$reported$and$≥$12$weeks … $to$40$or$80mg$AZL"M$or$10mg$RAM$for$22$weeks. … $After$2$weeks,$all$patients$were$ uptitrated$to$double$the$initial$dose$for$10$weeks^$subsequently, … $in$patients$without$normalized$office$BP.$24"h$ABP$was$recorded$at$ randomization$and$after$12$weeks … $Doses$were$doubled$after$2$weeks.

144. Allergy-Seasonal Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/allergy-seasonal_executive.pdf
     July 01, 2013 - prophylaxis, it requires a loading period during which it is applied four times daily for several weeks … How does effectiveness vary with long-term (months) or short-term (weeks) use? b. … How do adverse effects vary with long-term (months) and short-term (weeks) use? b. … How do effectiveness and adverse effects vary with long-term (months) or short-term (weeks) use? … How do effectiveness and adverse effects vary with long-term (months) or short-term (weeks) use?

145. TND-0543_05-24-2013 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0543_05-24-2013.pdf
     January 01, 2013 - normal chest radiograph, occurring with or without phlegm production, usually lasting less than 3 weeks

146. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/preterm-birth-terbutaline-pump_disposition-comments.pdf
     September 01, 2011 - Research Review Citation: Gaudet, L., Singh, K., Weeks L., Skidmore, B., Tsouros, S., Tsertsvadze, … Response Peer Reviewer 1 Executive Summary What is meant by difference sin “means” – was this weeks … Weeks Peer Reviewer 5 Introduction " Unfortunately, digital examination of the cervix in early labor … Ananth et al6, in viewing over 17 million births from 1990-99 found that while deliveries <37 weeks … Peer Reviewer 1 Methods (Study Section) The pump was commonly used among women less than 24 weeks

147. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/atypical-antipsychotics-off-label_executive.pdf
     January 01, 2007 - with an atypical antipsychotic plus an SRI antidepressant is not more effective than an SRI alone at 8 weeks … with psychotic features, olanzapine and olanzapine plus fluoxetine were compared with placebo for 8 weeks … evidence that olanzapine, whether used as monotherapy or augmentation, does not improve outcomes at 8 weeks … stress disorder (PTSD) We found four trials of risperidone and two trials of olanzapine of at least 6 weeks … Two trials of 8 weeks duration support the superiority of risperidone over placebo in improving serious

148. Rheumatoid-Arthritis-Medicine Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-medicine_executive.pdf
     April 01, 2012 - two oral DMARDs, improved ACR 50 response rates, disease activity scores, but no difference at 56 weeks … patients with early RA, significantly lower radiographic progression and fewer eroded joints at 56 weeks … Low More rapid improvement in functional capacity by 28 weeks but no differences by 56 weeks.

149. Research Protocol: Safety of Vaccines Used for Routine Immunization in the United States (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/safety-vaccines-protocol.pdf
     January 30, 2020 - (Rotarix); routine 6 through 32 weeks (RotaTeq); routine Tetanus, diphtheria, & acellular pertussis … use in the United States, 2019 Vaccine Brand name(s) Age range DTaP-HepB-IPV Pediarix 6 weeks … through 6 years DTaP-IPV/Hib Pentacel 6 weeks through 4 years DTaP-IPV Kinrix Quadracel 4 years … through 6 years MMR-V ProQuad 12 months through 12 years DTaP-IPV-Hib-HepB Vaxelis* 6 weeks through … (Hib) PedvaxHIB ActHIB Hiberix 2 months through 5 years (PedvaxHIB, ActHIB); if at risk 6 weeks

150. Management and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/binge-eating_clinician.pdf
     May 01, 2016 - Efficacy studies only measured outcomes at the end of treatment (8 weeks to 6 months) and had no long-term … Efficacy studies of pharmacological interventions only measured outcomes at the end of treatment (6 to 16 weeks

151. Disposition of Comments for CER 211: Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
     December 20, 2018 - A similar response was seen for ACR(20/50/70/90) at weeks 24 and 52. … At weeks 12 and 52, the proportion of patients who achieved MCID in SF-36 PCS was 75.6% (p=0.016 vs … The IMAGE study (8 weeks to 4 years) 24. … (70.7% vs. 49%; p<0.001).” – The COMET trial reported on the primary endpoint at 52 weeks. … prior to 52 weeks were not assessed.

152. Comparative Effectiveness Review No. 272_Genitourinary Syndrome of Menopause: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-272-genitourinary-syndrome-executive-summary.pdf
     July 01, 2024 - Most studies of hormonal interventions followed participants for 12 weeks, the longest followup period … treatments, suggests that symptoms begin improving within 1- 2 months and continue to improve through 12 weeks … In 6 of 10 studies that evaluated endometrial stimulation up to 36 weeks, vaginal estrogen was associated

153. Glaucoma-Treatment Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-treatment_surveillance.pdf
     January 01, 2013 - .6 1 study found that brimonidine-timolol FC achieved the same mean IOP as latanoprost at 12 weeks … BPLx12 weeks Mean change in IOP Efficacy: T2345 showed non-inferiority to BPL from day 15. … PF timololx12 weeks Mean change in IOP at 3 daily time points at weeks 2, 6, and 12 Efficacy: Tafluprost … latanoprost qd or switch to latanoprost+dorzolamide/timolol FC bid at 4 weeks if IOP still>20, with … switch to brimonidine at 8 weeks if IO<20 still not achieved IOP and visual function at 12 months

154. Carbohydrate-Intake-Prepub-Final-Research-Table-Rct (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-prepub-final-research-table-rct.xlsx
     May 29, 2025 - possible, this is rated for the measure of interest at the main timepoint of interest (e.g., GWG at 35-37 weeks

155. Traumatic-Brain-Injury-Rehabilitation Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/traumatic-brain-injury-rehabilitation_executive.pdf
     June 01, 2012 - Despite their many similarities, interventions based on this model of care varied in duration from 6 weeks … 241, 43 6 weeks 237, 42 8 weeks 142 16 weeks 330, 34, 35 6 months 331-33 9 months 144 Note: This … treated within 3 months of injury (Salazar 2000)42 Inpatient hospital rehabilitation program (8 weeks … moderate to severe TBI (Cicerone 2004; Cicerone 2008)34, 35 Intensive cognitive rehabilitation (16 weeks … ) vs. standard rehabilitation (16 weeks) Community-based employment at end of treatment Statistically

156. Long COVID Models of Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/long-covid-protocol.pdf
     February 18, 2023 - acute coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, typically last ~2 to 4 weeks … including postural orthostatic tachycardia syndrome).1,2,5,6 The duration of long COVID ranges from weeks … Department of Health and Human Services, “The signs, symptoms, and conditions are present four weeks … Health and Care Excellence reserves the term “post-COVID-19 syndrome” for symptoms lasting at least 12 weeks … 11 and uses the term “ongoing symptomatic COVID- 19” for symptoms at 4 to 12 weeks.

157. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/09_infectiousdisease_potential_high_impact_june_2012.pdf
     January 01, 2012 - of boceprevir plus IFN/RBV or 24 weeks of boceprevir plus IFN/RBV for 24 or 48 weeks) or 48 weeks … of placebo with IFN/RBV. 3 Overall, SVR at 48 weeks was achieved by 65% of patients in the boceprevir … In the control arm, 44% of patients achieved an SVR after 48 weeks of IFN/RBV. 4 In a second phase … Samples were taken once weekly for 10 weeks; after 5 weeks, the copper-containing and noncopper items … This is a direct result of current TB testing methods, which require weeks to deliver a definitive

158. Effects of Dietary Sodium and Potassium Intake on Chronic Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/sodium-potassium_research-protocol.pdf
     April 18, 2017 - • Timing o Studies reporting on an intervention period of at least four weeks will be eligible … • Study design o Parallel RCTs and cross-over RCTs with a washout period of two weeks or more … • Study design o Parallel RCTs and cross-over RCTs with a washout period of two weeks or more … • Study design o Parallel RCTs and cross-over RCTs with a washout period of two weeks or more … • Study design o Parallel RCTs and cross-over RCTs with a washout period of two weeks or more

159. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pepticulcer_hi_impact.pdf
     January 01, 2012 - the solution. 3 The company recommends a starting dose of 500 ova, taken orally once every 1 to 3 weeks … , with titration to a 1,000 ova per dose if no response is seen after 8 weeks (four treatments). 3 … The company notes that initial response may require several weeks and, because helminths are short-lived … After 24 weeks of treatment, 54% of patients treated with teduglutide were able to reduce the number … absorption of nutrients; however, somatropin has not been evaluated in patients with SBS for longer than 4 weeks

160. Surveillance Report: Masks for Prevention of COVID-19 in Community and Healthcare Settings (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/masks-prevention-covid-surveillance-report.pdf
     July 17, 2020 - Chandler Weeks, M.P.H. Marian S. McDonagh, Pharm.D. … Suggested citation: Chou R, Dana T, Jungbauer R, Weeks C, McDonagh M.